19
Dec
2017
Oblique Therapeutics has yet again received grants from Vinnova
This year we received funding for 3 different development projects:
- A new class of selective antagonistic TRPV1 for pain therapyA project we continue to get funded for.
In collaboration with KI.
- Engineering of nano-sized membrane vesicles for intracellular delivery of therapeutic antibodiesDesigning a new technology to get antibodies inside the cell
A project in collaboration with KTH, KI and SLU
- Improved cancer diagnostic and drug developmentA project in collaboration with RISE among others
